Meeting
2015 ASCO Annual Meeting
The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer.
Authors
Simon Chowdhury
Guy's King's and St Thomas Hospitals, London, United Kingdom
Simon Chowdhury , Richard Davidson , Alex Coppell , Hossein Mobasheri , Anny Stari , Robert Snijder , Cecil Treadwell , Axel S. Merseburger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT02288247
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS5083)
DOI
10.1200/jco.2015.33.15_suppl.tps5083
Abstract #
TPS5083
Poster Bd #
70a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb
Poster
2022 ASCO Genitourinary Cancers Symposium
CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith
Poster
2017 ASCO Annual Meeting
Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Evan Y. Yu
Poster
2015 ASCO Annual Meeting
Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edwin M. Posadas